

# THE LEADING INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE IN EUROPE

11<sup>th</sup> ImmunoTherapy of Cancer Conference  
April 3 - 5, 2025 • Munich, Germany



CCC MÜNCHEN  
COMPREHENSIVE  
CANCER CENTER



WOLFGANG  
WILMANN'S  
STIFTUNG



Deutsches Konsortium für  
Translationale Krebsforschung



CECOG ACADEMY  
Central European Cooperative Oncology Group

## SCIENTIFIC PROGRAMME



# WELCOME TO ITOC11!

The 11th ImmunoTherapy of Cancer Conference (ITOC11) held from April 3 - 5, 2025 is a European meeting providing a global platform for translational research in the field of immuno-oncology as well as a forum for discussion of early clinical translation and to address its unique challenges.

ITOC11 is organised by the WMA GmbH in scientific cooperation with the ITOC Association, the Tumor Centre in Munich (TzM), the German Cancer Consortium (DKTK), the CECOG Academy, the CAHON, the Wolfgang Wilmanns Stiftung as well as the Comprehensive Cancer Center Munich (CCCM) in Munich.

The main goal of the series of ITOC conferences is to provide a unique platform for discussions where all those dedicated to the immunotherapy of cancer can exchange their knowledge and latest findings to advance the oncology drug development and delivery.



# See you there!



# ITOC11 COMMITTEES

## ITOC11 Conference President

- Michael von Bergwelt (LMU, CCC, DKTK, Munich, Germany)

## ITOC11 Chairmen of the Scientific Committee


- Sebastian Kobold (Ludwig-Maximilians-Universität, Munich, Germany)
- Volkmar Nuessler (TZM, Munich, Germany)

## ITOC11 Scientific Committee

- Niroshana Anandasabapathy (Weill Cornell New York, NY, United States)
- Michael Bergmann (Medical University Vienna, Austria)
- Mascha Binder (Universitätsspital Basel, Switzerland)
- Tanja D. de Gruijl (Cancer Center Amsterdam, The Netherlands)
- Alexander Eggermont (Cancer Center Amsterdam, The Netherlands)
- Ulrich Jäger (Medical University of Vienna, Austria)
- Sebastian Kobold (Ludwig-Maximilians-Universität, Munich, Germany)
- Volkmar Nuessler (Munich, Germany)
- Johanna Olweus (Institute for Cancer Research, University of Oslo, Norway)
- Chong-Xian Pan (Harvard Medical School, Boston, MA, United States)
- Pedro Romero (Translational Tumor Immunology Group, University of Lausanne, Switzerland)
- José Saro (CMO LCB-Novimmune, Switzerland)
- Stefani Spranger (Koch Inst. for Integrative Cancer Research at MIT, Cambridge, MA, United States)
- Marion Subklewe (Ludwig-Maximilians-Universität, Munich, Germany)
- Eric Tartour (Hopital Européen Georges-Pompidou, Paris, France)
- Christoph Zielinski (Medical University of Vienna, Austria)

## ITOC Association Board Members

- Sebastian Kobold (Ludwig-Maximilians-Universität, Munich, Germany)
- Volkmar Nuessler (Munich, Germany)
- Michael von Bergwelt (LMU, CCC, DKTK, Munich, Germany)
- Christoph Zielinski (Medical University of Vienna, Austria)



08.30

**Registration Opens**

09.30 - 09.40

**Welcome Addresses:** Michael von Bergwelt, Munich, Germany & Stefan Endres, Munich, Germany

09.40 - 11.10

**Plenary Session 1: Tumor Immunology Inside: Novel Players**

Chair: Christoph Zielinski, Vienna, Austria & Niroshana Anandasabapathy, New York, NY, United States

09.40 – 10.10

01.01. Neutrophils in cancer  
Béatrice Zitti, Geneva, Switzerland

10.10 – 10.40

01.02. Dendritic cells as orchestrators of cancer immunity  
Niroshana Anandasabapathy, New York, NY, United States

10.40 – 11.10

01.03. Tregs in the cancer environment  
Eliane Piaggio, Paris, France

11.10 - 11.40

Coffee Break

11.40 - 13.10

**Plenary Session 2: Expect the Unexpected: Factors Influencing Immune Therapies**

Chair: Lucie Heinzerling, Munich, Germany & Tanja de Gruijl, Amsterdam, Netherlands

11.40 - 12.10

02.01. The influence of circadian rhythm on IO agent efficacy  
Christoph Scheiermann, Geneva, Switzerland

12.10 - 12.40

02.02. Androgen influence on immunotherapy  
Megan Ruhland, Portland, OR, United States

12.40 - 13.10

02.03. Local production of glucocorticoids in cancer and its therapeutic relevance  
Matthew Taves, Bethesda, MD, United States

13.10 - 13.20

**Company Pitch - see page 12**

13.20 - 15.00

Lunch & Poster Viewing

15.00 - 17.00

**Plenary Session 3: New Targets and New Leads**

Chair: Andrea Schmidts, Munich, Germany & Pedro Romero, Lausanne, Switzerland

15.00 - 15.30

03.01. Proteostatic Stress Response as Novel Opportunity for Cancer Immunotherapy  
Zihai Li, Columbus, OH, United States

15.30 - 16.00

03.02. MultiOmics in pushing the frontiers in understanding the tumor microenvironment: Single cell resolution imaging  
Matteo Iannacone, Milan, Italy

16.00 – 16.15

03.03. KLK4 cleaves CXCR3 chemokines and confers immune escape and resistance to cancer immunotherapy  
Tobias Dreyer, Munich, Germany

16.15 – 16.30

03.04. Exploring immunotherapy resistance in primary and metastatic oral cancer using organoid technology  
Lili Szabó, Würzburg, Germany

16.30 – 16.45

03.05. Targeting PD-1 with self-delivering RNAi: preclinical advances and ongoing clinical evaluation in intratumoral Immunotherapy  
Melissa Maxwell, Marlborough, United States

16.45 – 17.00

03.06. Neoadjuvant chemoradiotherapy with ipilimumab and nivolumab in rectal cancer (CHINOREC): A prospective randomized, open-label, multicenter, phase II clinical trial  
Michael Bergmann, Vienna, Austria

17.00 - 18.00

**Plenary Session 4: Polyspecific Antibody Derivatives**

Chair: Juliane Walz, Tübingen, Germany & Michael Bergmann, Vienna, Austria

17.00-17.30

04.01. TCR and TCR mimetics x CD3 bispecific antibodies: Expand the reach of antibodies to intracellular targets  
José Saro Suarez, Geneva, Switzerland

17.30-18.00

04.02. Bispecific gamma-delta T-cell engagers (Gammabodies) against cancer  
Hans van der Vliet, Amsterdam, The Netherlands

18.00 - 20.00

**Networking Event and Poster Viewing (at the venue)**



## **08.30 – 09.30 Plenary Session 5: Pro and Con: Local vs Systemic Immunotherapy**

Chair: Mascha Binder, Basel, Switzerland & Niels Halama, Heidelberg, Germany

08.30 – 09.00 05.01. Pro-local immunotherapies  
Louisa von Baumgarten, Munich, Germany

09.00 – 09.30 05.02. Pro systemic immunotherapy  
Mascha Binder, Basel, Switzerland

## **09.30 – 10.30 Plenary Session 6: Playing with the Devil: Nociception in Cancer Immunotherapy**

Chair: Louisa von Baumgarten, Munich, Germany & Martin Kerschensteiner, Munich, Germany

09.30 – 10.00 06.01. Triggering alpha2adrenergic receptors for tumor rejection  
Jingjing Zhu, Louvain, Belgium

10.00 – 10.30 06.02. Neuro-immune regulation of ILC function in anti-tumor immunity  
Camilla Jandus, Geneva, Switzerland

10.30 – 11.00 Coffee Break

## **11.10 – 12.30 Plenary Session 7: Immune Monitoring – Omics Technology**

Chair: Carolin Mogler, Munich, Germany & Jürgen Ruland, Munich, Germany

11.00 – 11.30 07.01. Spatial profiling of the immune contexture in cancer: a novel translational way to attack 'cold' tumors  
Niels Halama, Heidelberg, Germany

11.30 – 12.00 07.02. Resolving the HLA-ligandome in cancer  
Juliane Walz, Tübingen, Germany

12.00 – 12.30 07.03. Liquid immunotranscriptomics-derived biomarkers for monitoring response to immunotherapy in metastatic cancer  
Pedro Romero, Lausanne, Switzerland

## **12.30 - 13.00 Satellite Symposium - see page 13**

Chair: Sebastian Kobold, Munich, Germany

13.00 – 14.30 Lunch & Poster Viewing

## **14.30 – 15.15 Plenary Session 8: ITOC 11 Lifetime Achievement Award**

Chair: Sebastian Kobold, Munich, Germany & Michael von Bergwelt, Munich, Germany

Advancing Cancer Therapy: From Cancer Immunoediting to Personalized Cancer Vaccines  
Robert D. Schreiber, St. Louis, MO, United States

## **15.15 - 16.30 Plenary Session 9: Advancing Cancer Vaccines**


Chair: Eric Tartour, Paris, France & Chong Xian Pan, Boston, MA, United States

15.15 – 15.45 09.01. Neoantigen selection in tumor and lessons from flu  
Paul G. Thomas, Memphis, TN, United States

15.45 – 16.15 09.02. Dysfunctional translation generates aberrant, immunogenic peptides  
Tanja de Gruijl, Amsterdam, The Netherlands

16.15 – 16.30 09.03. Preliminary immunogenicity results from the dose escalation phase of a first-in-human study of the mRNA-based cancer vaccine CVGBM in patients with newly diagnosed MGMT-unmethylated glioblastoma  
Sandra Lazarro, Tübingen, Germany

16.30 - 17.00 Coffee Break





**17.00 - 18.00 Plenary Session 10: Young Researcher Session (from submitted abstracts)**

Chair: Stefan Endres, Munich, Germany & Ralf Jungmann, Munich, Germany

17.00 – 17.15 10.01. CD44v6-specific CAR-NK cells: a novel approach to precision medicine in bladder cancer  
Iris Lodewijk, Madrid, Spain

17.15 – 17.30 10.02. Targeting CSF1R+ myelo-monocytic cells enhances CAR-T cell response in B cell lymphoma  
David Stahl, Cologne, Germany

17.30 – 17.45 10.03. Immunosensitizing effect of TLR agonist combination for the treatment of cold tumors  
Thomas Morin, Dijon, France

17.45 – 18.00 10.04. Adapter P329G-directed CAR T cells for modular targeting of lung cancer  
Sophia Stock, Munich, Germany

**18.00 - 19.00 Poster Viewing with Presenters**

**19.15 ITOC 11 Conference Dinner**



## **08.00 – 09.00 Plenary Session 11: What Cellular Therapies Need to Work**

Chair: Hendrik Poeck, Regensburg, Germany & Roland Ullrich, Cologne, Germany

08.00 – 08.30 11.01. The role of preconditioning in T cell therapy  
Michal Besser, Tel Aviv, Israel

08.30 – 09.00 11.02. The role of myeloid cells in CAR T cell failure  
Camille Bigenwald, Villejuif, France

## **09.00 – 10.30 Plenary Session 12 Engineering novel Cellular Immunotherapies**

Chair: Marion Subklewe, Munich, Germany & Dirk Busch, Munich, Germany

09.00 – 09.30 12.01. Novel targets of TCR therapies  
Johanna Olweus, Oslo, Norway

09.30 – 10.00 12.02. Adoptive Cell Therapy, ways to enhance them  
Sabine Heitzeneder, Stanford, CA, United States

10.00 – 10.30 12.03. RORing cancer with novel CAR T cells  
Michael Hudecek, Würzburg, Germany

10.30 – 11.00 Coffee Break

## **11.00 – 12.30 Plenary Session 13: Advancing Cellular Therapies with Combinations**

Chair: Ulrich Jäger, Vienna, Austria & Johanna Olweus, Oslo, Norway

11.00 – 11.30 13.01. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors  
Andreas Mackensen, Erlangen, Germany

11.30 – 12.00 13.02. Targeting TGFbeta-activated kinase-1 activation in microglia to reduce neurotoxicities of CAR T cell therapies  
Robert Zeiser, Freiburg, Germany

12.00 – 12.15 13.03. Ablation of FAS confers allogeneic CD3- CAR T cells with resistance to rejection by T cells and natural killer cells  
Silvia Menegatti, Suresnes, France


12.15 – 12.30 13.04. Silencing BRD4 to increase NK cell activity for adoptive cell therapy: a novel self-delivering RNAi approach  
Melissa Maxwell, Marlborough, United States

12.30 – 12.45 13.05. Autocrine glucocorticoid signaling in hormonally active cancers induces antigen expression for CAR-T cell therapy  
Marc Schauer, Würzburg, Germany

## **12.45 – 13.15 Plenary Session 14: Best Poster Awards & Closing Remarks**

Chair: Sebastian Kobold, Munich, Germany & Michael von Bergwelt, Munich, Germany

**13.15 – 14.15 Lunch & Farewell**



# POSTER PRESENTATIONS

## Poster Session 1 | Tumor Immunology

P01.01. - P01.03 Withdrawn

P01.04. Sensitivity of different cell lines to NK cell lysis  
Vladimir Jurisic, Kragujevac, Serbia

P01.05. IOMX-0675, a LILRB1/LILRB2 cross-specific antibody that reprograms the tumor microenvironment to trigger potent anti-tumor activity  
Stefan Bissinger, Martinsried, Germany

P01.06. ICMT inhibition as a targeted approach for increasing MHC-I expression and blocking immune evasion in ovarian cancer  
Ruiqian Zhang, Hong Kong, Hong Kong

P01.07. The Role of PP2Ac in Regulating Immune Evasion in High Grade Serous Ovarian Cancer  
Xin HE, Hong Kong, Hong Kong

P01.08. PVR-CD226 interaction regulates IL-10 production during human T cell differentiation  
Ester Lozano, Barcelona, Spain

P01.09. Fas-L mediated death of activated intratumoral T cells drives secondary resistance to Treg depletion in cancer  
Chen Qing, London, United Kingdom

P01.10. Promoter methylation facilitates escape from specific immune responses against tumor-associated antigens across cancer types and can be overcome by demethylating agents  
Martin Thelen, Cologne, Germany

P01.11. Withdrawn

P01.12. Impact of glutamate metabolism and its inhibition on melanoma development and immune cells  
Patrizia Stoitzner, Innsbruck, Austria

P01.13. SECN-15: An antisense oligonucleotide-based approach to target expression of Neuropilin-1 induces anti-tumor activity in vivo and boosts efficacy of checkpoint inhibitors  
Andre Maaske, Planegg, Germany

P01.14. Intracellular and extracellular biochemical functions of V-domain Ig-containing suppressor of T cell activation are regulated by crucial factors of tumour microenvironment  
Vadim Sumbayev, Chatham Maritime, United Kingdom

P01.15. Prostanoid-insensitive chimeric antigen receptor modified T cells mediate therapeutic efficacy in solid cancer models  
Lisa Gregor, Munich, Germany

P01.16. GDF-15 inhibition overcomes treatment resistance to platinum-based chemoimmunotherapy  
Neha Vashist, Planegg-Martinsried, Germany

P01.17. Characterization of Neutrophil Subpopulations in Pancreatic Cancer Through a High-Dimensional Surface Marker Screen  
Nilofer Abdul Razak, Gräfelfing, Germany

P01.18. Withdrawn





# POSTER PRESENTATIONS

## Poster Session 2 | Mode of action of Immune Therapies

P02.01. Developing new and effective strategies for adoptive T- cell therapy in pediatric gliomas  
Or Zohar, Tel Aviv, Israel

P02.02. The Influence of Fecal Supernatants from Melanoma Patients on CAR T Cell Cytotoxicity and Immune Modulation  
Ying Wang, München, Germany

P02.03. Artificial targets for functional characterization of CAR T cells  
Borgelt, Bergisch Gladbach, Germany

P02.04. Developing T cell bispecific antibodies with reduced-affinity anti-CD3 binders for a potent, efficacious, and low-cytokine response  
Omar Abdelmotaleb, Schlieren, Switzerland

P02.05. GDF-15 neutralization enhances T cell infiltration in solid tumor models  
Arman Oner, Munich, Germany

P02.06. Chimeric VSV-NDV mediates a multifaceted immune response in solid cancers which is enhanced by expression of high-affinity soluble PD-1  
Jennifer Altomonte, Munich, Germany

P02.07. The combination of a STING agonist and IL15 efficiently reverses the immunosuppressive tumor microenvironment in a complex primary human organoid model  
Daphni Ammon, Vienna, Austria

## Poster Session 3 | New Targets and New Leads

P03.01. Generation and characterization of recombinant Vpx coupled to cell penetrating peptides  
Selin Aidin, Munich, Germany

P03.02. The prognostic role of glycodeclin through the interaction with the tumor microenvironment in NSCLC  
Lisa Strotmann, Heidelberg, Germany

P03.03. Granulopoiesis and thrombopoiesis aberrantly synergize in cancer to promote tumor progression  
Bojan Smiljanov, Munich, Germany


P03.04. Targeting CXCR4: Implications for Clonal Dynamics and MRD Assessment in Acute Myeloid Leukemia  
Enise Ceran, Heidelberg, Germany

P03.05. scFv-dependent anti-tumor efficacy of CAR-T cells targeting novel antigens in Acute Myeloid Leukemia  
Shifaa Abdin, Heidelberg, Germany

P03.06. EGFL7, an angiogenic factor, induces immunosuppression in malignant glioma  
Sukrit Mahajan, Dresden, Germany

## Poster Session 4 | Polyspecific Antibody Derivatives

P04.01. CSF1R-targeting T cell engaging bispecific antibodies for Acute Myeloid Leukemia treatment  
Thomas Janert, München, Germany



# POSTER PRESENTATIONS

## Poster Session 6 | Cancer Vaccines

P06.01. Survivin-based vaccine induces durable tumor regression when integrated with specific sequential antiangiogenic and immune checkpoint therapies

Fanny Méjean, Paris, France

P06.02. Enhancing Cancer Immunotherapy through Synthetic Biology: A Novel Heterologous Prime-Boost Strategy

Ilaria Esposito, Roma, Italy

## Poster Session 7 | Young Researcher Session

P07.01. Modular targeting of acute myeloid leukemia with anti-P329G adapter CAR T cells

Sophia Stock, Munich, Germany

P07.02. Pembrolizumab associated to chemotherapy in solid tumor: A retrospective study about 11 cases

Meryem Boudjerda, Constantine, Algeria

P07.03. A20 as a novel immune checkpoint in KRAS-driven lung adenocarcinoma

Monika Homolya, Vienna, Austria

P07.04. Mantle Cell Lymphoma in sight: development of anti-ROR1 CAR T-cell therapy, and enhancement of its safety profile by iCasp9 suicidal gene expression

Madalina Nistor, Cluj-Napoca, Romania

P07.05. Overcoming endothelial cell anergy by VEGFR2 inhibition to enhance CAR T cell response in aggressive B cell lymphoma

Lilli Schlözer, Cologne, Germany

## Poster Session 8 | Cellular Therapies (including combinations)

P08.01. A combinatorial therapy for bladder cancer: epigenetic inhibitor and CAR-NK cells

Lucia Morales, Madrid, Spain

P08.02. Adoptive cell therapy with Cytokine-Induced Killer cells armed with immunotools against HER-2 expressing breast cancer.

Ngo Hieu, Padova, Italy

P08.03. Eliminating operator errors in Flow analytics: dried reagents and fully automated flow gating provide fast and robust CAR T cell analytics

Cesar Evaristo, Bergisch Gladbach, Germany

P08.04. Impact of variability of CD4+/CD8+ T cell ratios on the functional properties of CAR T cell products

Cesar Evaristo, Bergisch Gladbach, Germany

P08.05. Dried antibody cocktails are setting the benchmark for fast and robust CAR T cell flow cytometric analysis

Borgelt, Bergisch Gladbach, Germany

P08.06. Optimizing promoter systems to enhance cytokine response in CAR T cells for tumor therapy

Lisa Steger, Erlangen, Germany


P08.07. Evaluation of CAR T cell function in advanced 3D heterospheroid models reveals monocyte-dependent protection against cancer cell killing

Natasha Madsen, Hørsholm, Denmark

P08.08. Withdrawn

P08.09. Robust ex-vivo expansion of tumour-infiltrating lymphocytes from ovarian cancer biopsies using dendritic cells derived from the leukemic cell line DCOne

Satwinder Kaur Singh, Stockholm, Sweden



# SCIENTIFIC INFORMATION

## Projection and Technical Setting

PowerPoint is the only communication tool available in the session hall. Overhead projection, slide projection or flipcharts are not available.


- Speakers are kindly asked to observe that only the computer provided by the venue may be used for showing your presentations. PowerPoint presentations can be checked and handed in at the speakers' preview desk or uploaded via USB Stick in the lecture room directly.
- All PowerPoint presentations should be checked/handed in at least 2 hours before the session starts.
- If you are doing more than one speech during the congress, you may upload all your presentations at the same time and they will be sent to the session hall at the time of your session.
- The PowerPoint handling and distribution system is optimized for MS PowerPoint 2007 (Office 2007) and "\*.pdf" (Adobe Acrobat)-files. The uploading of "DVD-Movies" is not supported.
- The supported data media is USB-Memory Key. You may want to carry a second key as a back-up in case there is any insoluble technical problem. All needed files (including the movie files!) - have to be saved on the data media. Presentations can also be taken off speakers notebooks at the Preview centre.
- The fonts that are used in the presentations should be "Latin-based fonts". If the speaker needs special fonts, they should be stored as "embedded fonts" with the presentation (File -> save as "name of presentation" and under "tools" -> save options mark the checkbox "embed True type fonts" and select "embed all characters").
- When using mathematical symbols please use these which are available under Latin fonts (unicode or DOS: Western Europe). These can be shown without any problems in Office 2007.
- As format for embedded movies "MPEG2 - movies" are preferred (but can also be \*.avi, \*.wmv ). If Codecs are used, the Code package Divx in the current version, which can be found under [www.divx.com](http://www.divx.com), should be chosen.
- Presentations should be saved as "\*.ppt", "\*.pptx" ( = PowerPoint) or "\*.pps", "\*.ppsx" (=PowerPoint Slideshow) - file and movies as separate files on the data media.
- The computers and projectors will be set up and optimised for resolution ratio 16:9.
- These guidelines should be seen as a matter of improving the effectiveness of the preview system and in consequence also the speakers comfort.

## Speaking Time

The chairpersons will be strict in allowing no more than the time allotted to presentations and discussions following the presentations. Remember to allow some time for the changeover of speakers and chairperson's introduction, and for questions and discussion.

## Commercial Disclosure information

Authors are requested to disclose possible conflicts of interest on the first slide. A conflict of interest is any situation in which a speaker or immediate family members have interests, and those may cause a conflict with the current presentation. Conflicts of interest do not preclude the delivery of the talk, but should be explicitly declared. These may include financial interests (e.g. owning stocks of a related company, having received honoraria, consultancy fees), research interests (research support by grants or otherwise), organisational interests and gifts.



# Moleculent

Thursday, April 3, 2025

13.10 - 13.20 hrs

Presenter: Jeroen Aerts, Solna, Sweden



# SATELLITE SYMPOSIUM



GILEAD



Kite

Friday, April 4, 2025


12.30 - 13.00 hrs

Gilead Satellite Symposium

## Phase 2 Study: Efficacy and Safety of Axicabtagene Ciloleucel in 2L PMBCL in Germany

Clinical and translational aspects of the PRIME CAR Study with axi-cel for 2L PMBCL


- Speaker: Dr. Imke Karsten  
University Hospital Münster, Germany





11th ImmunoTherapy of Cancer Conference  
April 3 - 5, 2025 Munich, Germany  
Organiser: WMA GmbH


Level 2





# EXHIBITORS

EXHIBITOR	STAND #
MedChem Express	4
Beckman Coulter	6
Proteome Sciences	8
Omics Empower	12
Bio-trend   CliniSciences	14
Miltenyi Biotec	16
Bio-Techne	18
Vicinity	20
Vectorbuilder	22
Janvier Labs	24
Akoya	26
AID GmbH	28





# GENERAL INFORMATION

## ORGANIZER | SPONSORSHIP | EXHIBITION MATTERS

### WMA GmbH

#### Conference & Society Management

- Contact: Catherine Tomek
- E-mail: [itoc@wma.co.at](mailto:itoc@wma.co.at)
- Tel.: +43 1 405 13 83 18
- Website: [www.wma.co.at](http://www.wma.co.at)



## CONFERENCE VENUE

Klinikum der Universität München  
Campus Großhadern  
Lecture Room 3  
Marchioninistrasse 15  
80336 Munich, Germany

## HOW TO REACH THE VENUE - IMPORTANT INFORMATION

The underground line between Implerstraße and Großhadern Hospital is currently being renovated. The refurbishment will enter its second phase from 10 March 2025, meaning that there will be no underground service in the direction of Großhadern Hospital. Both underground lines (U3 and U6) will run to Fürstenried West instead. Although there will be a bus service between Bruderermühlstraße and Großhadern Hospital, we recommend travelling to Fürstenried West and then taking bus 56 to the 'Klinikum Ost' stop. From there you can either walk through the main entrance of the hospital on the first floor (Besucherstraße) to the very back of the auditorium wing, or you can change at the same stop to bus 266 in the direction of Planegg and take another stop (Klinikum Nord) - directly opposite the main entrance of the auditorium wing.

There will also be a bus service between Großhadern Hospital and the S-Bahn station 'Donnersberger Brücke'. However, you can also take bus 56 from the 'Pasing' S-Bahn/train station in the direction of Fürstenried West and get off at the 'Klinikum Ost' station.

A further hurdle, which was announced only a week ago for immediate effect, is that the access around the hospital between the underground station 'Klinikum Großhadern' and the main entrance to the hospital is closed until the end of the year.

We therefore strongly recommend travelling via Klinikum Ost (main entrance to the hospital) and/or Klinikum Nord (main entrance to the lecture theatre wing).

## Cancellations and Refunds

Registration fees may be refunded if written cancellation has been received as follows:

until December 16, 2024: 50% refund

after December 16, 2024: no refund

The cancellation will not be effective until a written acknowledgement from the Congress Office is received. In the case of over-payment or double payment, refund requests must be made in writing and sent to the Congress Office by e-mail. No refunds will be granted for unattended events or early termination of attendance, in case of cancellation of speakers or any other incidents during the conference, which are beyond the control of the conference organisers.

No exceptions to the refund policy can be made, including health or family issues. By registering for ITOC11, participants agree that neither the organising committee nor the Congress Office assume any liability whatsoever.

## Certificate of Attendance

Confirmations of attendance will be issued electronically after the conference to all registered participants after completion of an online survey.

## Accreditation

The 11th ImmunoTherapy of Cancer Conference, Munich, Germany (April 3 - 5, 2025) has been submitted for continuing medical education credit points by the Bavarian State Chamber of Physicians | Bayerische Landesärzte-kammer (BLAEK).



# GENERAL INFORMATION

## Badges

For security reasons, badges will be checked upon access of the conference areas. Delegates are therefore requested to wear their badge at all times during the conference.

## Catering

- Coffee breaks and the welcome reception have been scheduled in the exhibition area. Exact times are listed in the programme overview.
- Lunch tickets had to be pre-ordered and cannot be purchased onsite.

## Currency

The official currency of Germany is the Euro (EUR).

## Exhibition

The exhibition is held on level 2 next to the main lecture room hall 3.

Entrance is free for registered delegates but limited to healthcare professionals, press and exhibitors.

## Insurance

By registering to the ITOC11, participants agree that neither the organising committee nor the congress office assume any liability whatsoever. Participants are requested to make their own arrangements for health and travel insurance. The conference fee does not include insurance.

## Language & Translation

The official language of the conference is English. No simultaneous translation is provided.

## Liability

In registering for ITOC11 participants agree that neither the organising committee nor the congress office assume any liability whatsoever. Participants are requested to make their own arrangements in respect of health and travel. Furthermore, the organisers cannot assume any liability for changes in the programme due to external or unforeseen circumstances and force majeure.

## Opening hours of the registration desk

April 3, 2025:	08.30 - 18.00 hrs CET
April 4, 2025:	07.45 - 18.30 hrs CET
April 5, 2025:	07.30 - 13.15 hrs CET

## Registration Details

Registration Fees in EUR (all fees include 19% German VAT)


	Early Bird until February 10, 2025	From February 11, 2025 to March 10, 2025	From March 11, 2025 and On-Site
Academia	EUR 465,-	EUR 565,-	EUR 665,-
Junior Participant <sup>(1)</sup>	EUR 115,-	EUR 145,-	EUR 190,-
Industry	EUR 765,-	EUR 865,-	EUR 965,-
Press / Media	no fee	no fee	no fee

<sup>(1)</sup> The "Junior Participant" registration is available for Students under 35 years of age. Please provide a copy of a student ID at the moment of your registration.

Payments were to be made without charges to the beneficiary.

Any bank charges will be claimed.

Please be informed that onsite payment by creditcard is preferred.





# GENERAL INFORMATION

## What is covered by the registration fee?

- Admission to all scientific sessions
- Admission to all poster sessions
- Admission to the exhibition
- Abstract book and programme
- Coffee Breaks
- Welcome Reception

## Twitter

The 11th ImmunoTherapy of Cancer Conference is present on Twitter @ITOCconference. We invite you to follow us on Twitter and to engage and discuss with your colleagues.

## Photographs, Video-Streaming, etc.

The Organiser may without the further consent of the participants use and release pictures and videos taken during the Conference for reports of the Conference and/or in future marketing materials. By registering to this conference attendees agree that photographs or sound or video recordings taken during the conference that could include recognizable images or voices of those in attendance may be posted on the conference website. All recordings are treated sensitively and discreetly. Names will not be published. The Conference is held in a public space, therefore we do not prohibit participants, exhibitors, sponsors, or news organisations from photographing, video or audio-taping some Conference activities. The organiser reserves the right to use images taken at the Conference with your photograph and/or likeness on social media and/or in future marketing materials. The organiser is NOT responsible for individual attendee's use of your image or likeness.

## Policies

ITOC11 is accessible to all registered delegates. Children and members of the public are not permitted in the exhibition area or any room hosting an industry activity. In addition, the ITOC11 conference asks delegates and faculty to refrain from taking children and accompanying adults to any sessions or practical demonstrations. In the event that children are required to enter the conference centre, they should be supervised by an adult at all times and observe the restrictions that apply to limited access areas. In the event that a member of public is invited to participate in the ITOC11 conference scientific programme, they should be accompanied by a qualified healthcare professional or ITOC11 representative observing the ITOC11 restrictions where appropriate.

## Poster Removal

The organisers cannot assume any liability for loss or damage of posters displayed in the poster area. **Posters that were not removed on Saturday, April 5, 2025 between 11.00 - 12.00hrs will be discarded and will neither be kept nor mailed to the author after the meeting.**

## Safety - Crime

Visitor safety is generally adequate, like in any other major European city. You can walk everywhere using common sense. Pick pocketing in heavily visited tourist zones or in public transport lines might be a concern. Unfortunately experience has shown that some basic precautionary measures should always be kept in mind in any city:

- Do not carry important items like flight tickets, passports etc. with you when visiting the conference or strolling through the city, leave them in the hotel safe during your stay. Rather carry a Xerox copy of your passport or an identity card with you.
- Try not to carry all documents, money, credit cards and other essential items and valuables in one bag. If it is lost or stolen, everything will be gone and might be difficult to replace on short notice, especially passports and visa to return to your country of residence.
- Take off your name badge when leaving the conference venue, it will make you easily identifiable as a tourist.

## Smoking Policy

ITOC11 is a "No-smoking-Conference".



# GENERAL INFORMATION

## Social Media Policy

ITOC11 supports the use of social media around its conferences and events in order to network with colleagues and friends attending the meeting. Please do however respect the ITOC11 social media guidelines, including the following:

### DOs:

- Follow ITOC11 on Twitter (@ITOCconference) and use the meeting hashtag to follow the latest updates and join in the conversation about the conference.
- You may tweet about content of the talks, unless the speaker explicitly asks you not to share either the entire talk or specific details or slides.
- Communicate in a respectful and considerate way, and show your criticism in a fair, constructive and professional manner.
- Do remember that people who will read your postings or tweets are not necessarily professionals, but also patients, policymakers, members of the media, and the general public.

### DON'Ts:

- The use of photography in oral and poster sessions at the ITOC11 conferences is allowed, unless indicated differently by the author on one or all of their slides or their poster. Hence posting pictures or videos of presentations (in parts or as a whole) carrying a "no picture" symbol on any social media platform, blogs, or websites, etc., is strictly prohibited.
- Do not capture or redistribute data presented at conferences as this may jeopardise the subsequent publication of the data in a scientific journal. Powerpoint presentations marked with a "no picture" symbol must not be photographed under any circumstances.

Do respect journal embargo policies and the work of your colleagues!

- Refrain from engaging in personal attacks or showing rude behaviour.
- Offensive and disrespectful behaviour, sales-oriented, self-promoting, or otherwise inappropriate comments will not be tolerated.
- Participants should not post copyrighted or trademarked material or material protected by other intellectual property rights.

The views and opinions posted on ITOC11's social media do not necessarily reflect the views, opinions, or policies of the ITOC association, its Board or membership. The ITOC reserves the right to remove comments it deems to be inappropriate.

## Staff

If you should have any questions, the congress staff will be pleased to help you.

## Networking Events

### Networking & Poster Viewing

Day: Thursday, April 4, 2025

Time: 18.00 hrs

Location: exhibition & poster area of the conference venue

*No fee for registered participants, but registration is mandatory!*

### Conference Dinner

Day: Friday, April 4, 2025

Time: 19.15 hrs

Location: Restaurant "Haderner Augustiner"

Contribution towards expenses EUR 70,-


Event for registered participants ONLY!

*Tickets had to be pre-ordered.*

## WiFi

Free WiFi (Bayern WLAN) is available for participants throughout the conference venue

For further general information, please also see [www.itoc-conference.eu](http://www.itoc-conference.eu)





EUR 3.800,-



EUR 3.800,-



EUR 3.800,-



EUR 3.800,-



EUR 2.900,-



EUR 1.200,-



EUR 10.000,-



EUR 3.800,-



EUR 3.800,-



EUR 2.500,-





# Moleculent

EUR 1.200,-



**Miltenyi Biotec**

EUR 3.800,-



**omics  
empower**

EUR 3.800,-



EUR 3.000,-



EUR 3.800,-



EUR 1.000,-



EUR 3.000,-



EUR 2.200,-



**Wilhelm Sander Stiftung**


Partnerin der Krebsforschung

EUR 3.000,-



EUR 1.000,-

**WOLFGANG  
WILMANNS  
STIFTUNG**



# SAVE THE DATES!

Mark your calendars and save the dates for the

## **12<sup>th</sup> ImmunoTherapy of Cancer Conference in 2026!** **March 12 - 14, 2026**

Join us as we convene once again to advance research, foster collaboration, and drive innovation in the field of cancer immunotherapy. Get ready to connect with leading experts, explore cutting-edge discoveries, and shape the future of cancer treatment.

Stay tuned for more details on the 2026 conference that promises to inspire, educate, and propel us closer to our shared goal of conquering cancer through immunotherapy.

#ITOC2026 #Immunotherapy #SaveTheDate

